Terminated PHASE4 INTERVENTIONAL 1-arm NCT01211314

Antihypertensive Efficacy of Fixed Combination Drug

Treatment of Essential Hypertension With Vasodip-Combo 20. Efficacy and Safety Evaluation With 24 h Ambulatory Blood Pressure Measurements

Sponsor: Dexcel Pharma Technologies Ltd.

Conditions Hypertension

Interventions Lercanidipine/enalapril fixed combination

Updated 7 times since 2017 Last updated: Jun 26, 2016 Started: Jan 31, 2011 Primary completion: Dec 31, 2011 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

sponsor decision

Other Hypertension trials with similar outcome

Browse all Hypertension trials

A PHASE4 clinical study on Hypertension, this trial is terminated or withdrawn. The trial is conducted by Dexcel Pharma Technologies Ltd. and has accumulated 7 data snapshots since 2011. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE4
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Terminated PHASE4
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE4

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dexcel Pharma Technologies Ltd.
Meir Medical Center

Data source: Meir Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Herzliya, Israel